Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) insider Robert Christopher Andrade sold 106,844 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the sale, the insider directly owned 217,675 shares of the company’s stock, valued at approximately C$3,619,935.25. This trade represents a 32.92% decrease in their position.
Fennec Pharmaceuticals Stock Performance
Fennec Pharmaceuticals stock opened at C$17.00 on Monday. Fennec Pharmaceuticals Inc. has a 52 week low of C$7.59 and a 52 week high of C$17.64. The stock has a fifty day moving average of C$15.18 and a 200-day moving average of C$12.36. The stock has a market capitalization of C$596.14 million, a P/E ratio of -141.67 and a beta of 3.55.
Institutional Investors Weigh In On Fennec Pharmaceuticals
A hedge fund recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned approximately 0.30% of Fennec Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 15.23% of the company’s stock.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
